Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zanubrutinib,Zanu2023-US-01,2023,USA,MDV,350,68,35,65,27.5,42,88,12,15,30,40,15,55,25,15,5,20,35,45,18,7,4,9,5,22,38,45,R-CHOP,DA-EPOCH-R,Rituximab,BR,8,5,7,25,40,30,15,45,40,60,2
Zanubrutinib,Zanu2023-EU-02,2023,Germany,Claim Database,420,72,40,60,26.8,38,85,15,12,28,42,18,52,28,14,6,18,32,50,20,8,5,10,6,20,35,42,R-CHOP,CVP,Rituximab,Bendamustine,7,6,9,28,42,32,12,48,40,65,3
Zanubrutinib,Zanu2022-JP-03,2022,Japan,MDV,280,65,30,70,24.5,50,90,10,18,32,38,12,60,22,12,6,22,38,40,15,6,3,8,4,25,40,48,R-CHOP,Hyper-CVAD,Rituximab,CVP,9,4,6,22,38,28,20,50,30,70,1
Zanubrutinib,Zanu2024-CA-04,2024,Canada,Claim Database,480,70,38,62,28.0,40,87,13,14,29,41,16,54,26,16,4,19,34,47,19,7,4,9,5,21,37,44,R-CHOP,Bendamustine,Rituximab,BR,8,5,7,26,41,31,14,46,40,62,2
